Migraine sufferers are often refractory to oral medications. Problems associated with commercially available triptan therapies for migraine may be overcome with topical regional neuroaffective (TRNA) therapy. Novel, proprietary topical triptan delivery (United States Patent No. 8 329 734 B2, granted December 2012) uniquely provides therapeutic benefit while minimizing both systemic and cerebral blood levels. Drug blood levels are unnecessary as the therapeutic effect is achieved directly by the drug’s action on un-myelinated nerve-endings below the skin surface at the back of the neck. Clearspring Pharmacy is a licensee of AfGin Pharma, LLC, and thereby authorized to compound these patented topical creams.
Aung-Din R. Topical Regional Neuro-Affective (TRNA) Therapy: Novel Ground-Breaking Triptan Drug Delivery for Treating Migraines. Drug Deliv-ery Technology. 2009; 9(9): 44-51.
Clearspring Pharmacy is licensed to provide Migraderm by AfGin Pharmac, LLC, holder of the US Patent. Read more…
Migraderm is a novel Topical Regional Neuro-Affective (TRNA) therapy for the treatment of migraine. Click here to see how it works.
Click here to read the full article on this novel ground-breaking triptan drug therapy for patients who have not responded to commercial meds.
Read more about Ronald Aung-Din, MD and the corresponding patent for his Migraderm therapy.